(1888PressRelease)
May 22, 2009 - The data presented at the American Thoracic Society (ATS) 2009 International Conference in San Diego show that QAB149, a long-acting beta2-agonist (LABA), significantly improved lung function from the first day of therapy to up to one year of treatment[1]. The data also reveal that all evaluated doses of QAB149 were well-tolerated and had a good overall safety profile[4],[5],[6].
All doses of once-daily QAB149 met the primary efficacy endpoint of significant improvement in FEV1 (forced expiratory volume in one second) versus placebo at twelve weeks.[3],[4],[5] This improvement was seen as early as five minutes post-dose and at every subsequent time point measured in each study[3],[4],[5]. In INVOLVE QAB149 (300µg and 600µg) also showed significant improvements over formoterol 12µg in trough FEV1 difference versus placebo at three months (170ml and 170ml vs. 70ml; p
###
